- Home
- RDCM vs PRQR Comparison
RDCM vs PRQR Comparison
Compare RDCM & PRQR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | RDCM | PRQR |
|---|---|---|
| Founded | 1985 | 2012 |
| Country | Israel | Netherlands |
| Employees | N/A | N/A |
| Industry | Computer peripheral equipment | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 270.2M | 244.1M |
| IPO Year | 1999 | 2014 |
Fundamental Metrics
Financial Performance| Metric | RDCM | PRQR |
|---|---|---|
| Price | $13.03 | $1.72 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 4 |
| Target Price | ★ $18.00 | $7.25 |
| AVG Volume (30 Days) | 134.0K | ★ 1.6M |
| Earning Date | 05-13-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $11.50 | N/A |
| Revenue Next Year | $9.74 | $13.92 |
| P/E Ratio | $16.35 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $10.41 | $1.33 |
| 52 Week High | $16.74 | $3.10 |
Technical Indicators
Market Signals| Indicator | RDCM | PRQR |
|---|---|---|
| Relative Strength Index (RSI) | 43.49 | 50.08 |
| Support Level | $12.93 | $1.37 |
| Resistance Level | $14.10 | $1.76 |
| Average True Range (ATR) | 0.53 | 0.13 |
| MACD | -0.10 | -0.00 |
| Stochastic Oscillator | 31.41 | 43.30 |
Price Performance
Historical ComparisonAbout RDCM Radcom Ltd.
Radcom Ltd Ltd is engaged in providing network intelligence, 5G ready cloud-native, network intelligence solutions for telecom operators transitioning to 5G. The company has a network intelligence solution for 5G namely Radcom ACE. Its products consist of Radcom Network Visibility, Radcom Service Assurance, and Radcom Network Insights. It has offices in Israel, the United States, Brazil, and India. Key revenue is derived from sales in North America.
About PRQR ProQR Therapeutics N.V.
ProQR Therapeutics NV is a biopharmaceutical company. It discovers and develops RNA therapeutics for patients with severe genetic rare diseases such as cystic fibrosis, Leber congenital amaurosis type 10, and dystrophic epidermolysis bullosa. The only reportable segment of the company is the discovery and development of different, RNA-based therapeutics. Geographically, the company operates in United States.